171 related articles for article (PubMed ID: 36579992)
1. Risk Factors, Patterns, and Distribution of Bone Metastases and Skeletal-Related Events in High-Risk Breast Cancer Patients.
Anwar SL; Avanti WS; Dwianingsih EK; Cahyono R; Suwardjo S
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4109-4117. PubMed ID: 36579992
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
3. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.
Jensen AØ; Jacobsen JB; Nørgaard M; Yong M; Fryzek JP; Sørensen HT
BMC Cancer; 2011 Jan; 11():29. PubMed ID: 21261987
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan.
Yamashiro H; Takada M; Nakatani E; Imai S; Yamauchi A; Tsuyuki S; Matsutani Y; Sakata S; Wada Y; Okamura R; Harada T; Tanaka F; Moriguchi Y; Kato H; Higashide S; Kan N; Yoshibayashi H; Suwa H; Okino T; Nakayama I; Ichinose Y; Yamagami K; Hashimoto T; Inamoto T; Toi M
Int J Clin Oncol; 2014 Oct; 19(5):852-62. PubMed ID: 24292334
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
8. Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
Anwar SL; Cahyono R; Prabowo D; Avanti WS; Choridah L; Dwianingsih EK; Harahap WA; Aryandono T
BMC Cancer; 2021 May; 21(1):590. PubMed ID: 34022845
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Anwar SL; Avanti WS; Nugroho AC; Choridah L; Dwianingsih EK; Harahap WA; Aryandono T; Wulaningsih W
World J Surg Oncol; 2020 May; 18(1):117. PubMed ID: 32473643
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
11. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
14. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.
van der Pol CB; Schweitzer ME; Di Primio G; Sampaio ML; Kielar A; Clemons M; Jaberi A
Breast Cancer Res Treat; 2014 Aug; 146(3):583-9. PubMed ID: 25007963
[TBL] [Abstract][Full Text] [Related]
19. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study.
Baek YH; Jeon HL; Oh IS; Yang H; Park J; Shin JY
Cancer Epidemiol; 2019 Aug; 61():104-110. PubMed ID: 31176960
[TBL] [Abstract][Full Text] [Related]
20. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
